Contribution of p38 MAPK Pathway to Norcantharidin-Induced Programmed Cell Death in Human Oral Squamous Cell Carcinoma
Open Access
- 16 July 2019
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (14) , 3487
Abstract
Norcantharidin (NCTD), a demethylated analog of cantharidin isolated from blister beetles, has been used as a promising anticancer agent; however, the underlying function of NCTD against human oral squamous cell carcinoma (OSCC) has not been fully understood. Here, this study was aimed to investigate the apoptotic effect and molecular targets of NCTD in human OSCC in vitro and in vivo. The anticancer effects of NCTD and its related molecular mechanisms were evaluated by trypan blue exclusion assay, live/dead assay, western blotting, 4-6-Diamidino-2-Phenylindole (DAPI) staining, flow cytometric analysis, Terminal Deoxynucleotidyl Transferase dUTP Nick end Labeling (TUNEL) assay, and immunohistochemistry. NCTD significantly inhibited cell growth and increased the number of dead cells in HSC-3 and HN22 cell lines. It induced the following apoptotic phenomena: (1) the cleavages of poly (ADP-ribose) polymerase and casepase-3; (2) increase in apoptotic morphological changes (nuclear condensation and fragmentation); (3) increase in annexin V-positive cells or sub-G1 population of cells. NCTD significantly activated the p38 mitogen-activated protein kinase (MAPK) pathway but inactivated the signal transducer and activator of transcription (STAT)3 pathway. A p38 MAPK inhibitor (SB203580) partially attenuated NCTD-induced programmed cell death (apoptosis) in both cell lines, whereas ectopic overexpression of STAT3 did not affect it. NCTD strongly suppressed tumor growth in the tumor xenograft bearing HSC-3 cells, and the number of TUNEL-positive cells increased in NCTD-treated tumor tissues. In addition, NCTD did not cause any histopathological changes in the liver nor the kidney. NCTD induced programmed cell death via the activation of p38 MAPK in OSCC. Therefore, these results suggest that NCTD could be a potential anticancer drug candidate for the treatment of OSCC.Keywords
This publication has 43 references indexed in Scilit:
- Norcantharidin, Derivative of Cantharidin, for Cancer Stem CellsEvidence-Based Complementary and Alternative Medicine, 2013
- Cardiotoxin III Inhibits Proliferation and Migration of Oral Cancer Cells through MAPK and MMP SignalingThe Scientific World Journal, 2013
- Antimetastatic Effects of Norcantharidin on Hepatocellular Carcinoma by Transcriptional Inhibition of MMP-9 through Modulation of NF-kB ActivityPLOS ONE, 2012
- Apoptotic Effect of Tolfenamic Acid in KB Human Oral Cancer Cells: Possible Involvement of the p38 MAPK PathwayJournal of Clinical Biochemistry and Nutrition, 2010
- Norcantharidin is a small-molecule synthetic compound with anti-angiogenesis effectLife Sciences, 2009
- A small-molecule metastasis inhibitor, norcantharidin, downregulates matrix metalloproteinase-9 expression by inhibiting Sp1 transcriptional activity in colorectal cancer cellsChemico-Biological Interactions, 2009
- Signal integration by JNK and p38 MAPK pathways in cancer developmentNature Reviews Cancer, 2009
- Suppression of growth of highly-metastatic human breast cancer cells by norcantharidin and its mechanisms of actionCytotechnology, 2009
- Dysregulated molecular networks in head and neck carcinogenesisOral Oncology, 2009
- MAP Kinases in the Immune ResponseAnnual Review of Immunology, 2002